Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents

• Published in: Vaccine Vol. 37; no. 12; pp. 1710 - 1719
• Main Authors: Vesikari, Timo, Østergaard, Lars, Beeslaar, Johannes, Absalon, Judith, Eiden, Joseph J., Jansen, Kathrin U., Jones, Thomas R., Harris, Shannon L., Maansson, Roger, Munson, Samantha, O'Neill, Robert E., York, Laura J., Perez, John L.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 14.03.2019; Elsevier Limited
• Subjects: Adolescence; Adolescents; Antigens; binding proteins; blood serum; Booster; complement; Complement factor H; Czech Republic; Data processing; Denmark; European Union; geometry; Germany; humans; Immune response; Immune system; Immunization; Immunogenicity; immunologic memory; Immunological memory; Influenza; Interactive systems; Internet; Invasive meningococcal disease; Meningococcal disease; Persistence; Proteins; Psoriasis; Quantitation; Randomization; risk; Safety; Schedules; secondary immunization; Serogroup B; serotypes; Skin diseases; Sweden; Teenagers; United States; Vaccination; Vaccine; Vaccines; Young adults; United States > US; Denmark; Czech Republic; Sweden; United States; Germany; Persistence; Vaccine; Serogroup B; Adolescents; Booster; Meningococcal disease

The period of heightened risk of invasive meningococcal disease in adolescence extends for >10 years. This study aimed to evaluate persistence of the immune response to the serogroup B meningococcal (MenB) vaccine MenB-FHbp (Trumenba®, Bivalent rLP2086) under two- and three-dose primary vaccinati...